Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders

M. Porta, M. Gamba, G. Bertacchi, P. Vaj

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Objectives - To investigate the safety and efficacy of ultrasound guided botulinum toxin type A (BTX-A) injections into salivary glands for the treatment of sialorrhoea in patients with neurological disorders. Methods - The parotid and submandibular glands of 10 patients were injected with BTX-A using ultrasound guidance. Before injection, the baseline rate of salivation was assessed using a visual analogue scale. Postinjection, assessments were repeated at regular intervals for up to 1 year. Results - Of the 10 patients treated, nine (90%) reported a subjective reduction in salivation post-treatment and one patient (10%) found no improvement. Visual analogue scale scores showed a reduction of 55% in the mean rate of salivation for all patients and a reduction of 60.8% for the group of responders. No serious adverse events occurred and no procedure related complications were reported. Conclusions - This is the first study to report (1) the injection of BTX-A (BOTOX®) into both parotid and submandibular glands, and (2) the use of ultrasound guidance during the administration of BTX-A into salivary glands. The results suggest that the technique is safe and that BTX-A injections are effective for the treatment of sialorrhoea in patients with neurological disorders.

Original languageEnglish
Pages (from-to)538-540
Number of pages3
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume70
Issue number4
DOIs
Publication statusPublished - Apr 2001

Fingerprint

Sialorrhea
Type A Botulinum Toxins
Nervous System Diseases
Salivation
Injections
Submandibular Gland
Parotid Gland
Salivary Glands
Visual Analog Scale
Therapeutics
Safety

Keywords

  • Botulinum toxin type A
  • Neurological diseases
  • Sialorrhoea
  • Ultrasound

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Psychiatry and Mental health

Cite this

Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. / Porta, M.; Gamba, M.; Bertacchi, G.; Vaj, P.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 70, No. 4, 04.2001, p. 538-540.

Research output: Contribution to journalArticle

@article{10a94d7513fb42e69067d0abd028a554,
title = "Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders",
abstract = "Objectives - To investigate the safety and efficacy of ultrasound guided botulinum toxin type A (BTX-A) injections into salivary glands for the treatment of sialorrhoea in patients with neurological disorders. Methods - The parotid and submandibular glands of 10 patients were injected with BTX-A using ultrasound guidance. Before injection, the baseline rate of salivation was assessed using a visual analogue scale. Postinjection, assessments were repeated at regular intervals for up to 1 year. Results - Of the 10 patients treated, nine (90{\%}) reported a subjective reduction in salivation post-treatment and one patient (10{\%}) found no improvement. Visual analogue scale scores showed a reduction of 55{\%} in the mean rate of salivation for all patients and a reduction of 60.8{\%} for the group of responders. No serious adverse events occurred and no procedure related complications were reported. Conclusions - This is the first study to report (1) the injection of BTX-A (BOTOX{\circledR}) into both parotid and submandibular glands, and (2) the use of ultrasound guidance during the administration of BTX-A into salivary glands. The results suggest that the technique is safe and that BTX-A injections are effective for the treatment of sialorrhoea in patients with neurological disorders.",
keywords = "Botulinum toxin type A, Neurological diseases, Sialorrhoea, Ultrasound",
author = "M. Porta and M. Gamba and G. Bertacchi and P. Vaj",
year = "2001",
month = "4",
doi = "10.1136/jnnp.70.4.538",
language = "English",
volume = "70",
pages = "538--540",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders

AU - Porta, M.

AU - Gamba, M.

AU - Bertacchi, G.

AU - Vaj, P.

PY - 2001/4

Y1 - 2001/4

N2 - Objectives - To investigate the safety and efficacy of ultrasound guided botulinum toxin type A (BTX-A) injections into salivary glands for the treatment of sialorrhoea in patients with neurological disorders. Methods - The parotid and submandibular glands of 10 patients were injected with BTX-A using ultrasound guidance. Before injection, the baseline rate of salivation was assessed using a visual analogue scale. Postinjection, assessments were repeated at regular intervals for up to 1 year. Results - Of the 10 patients treated, nine (90%) reported a subjective reduction in salivation post-treatment and one patient (10%) found no improvement. Visual analogue scale scores showed a reduction of 55% in the mean rate of salivation for all patients and a reduction of 60.8% for the group of responders. No serious adverse events occurred and no procedure related complications were reported. Conclusions - This is the first study to report (1) the injection of BTX-A (BOTOX®) into both parotid and submandibular glands, and (2) the use of ultrasound guidance during the administration of BTX-A into salivary glands. The results suggest that the technique is safe and that BTX-A injections are effective for the treatment of sialorrhoea in patients with neurological disorders.

AB - Objectives - To investigate the safety and efficacy of ultrasound guided botulinum toxin type A (BTX-A) injections into salivary glands for the treatment of sialorrhoea in patients with neurological disorders. Methods - The parotid and submandibular glands of 10 patients were injected with BTX-A using ultrasound guidance. Before injection, the baseline rate of salivation was assessed using a visual analogue scale. Postinjection, assessments were repeated at regular intervals for up to 1 year. Results - Of the 10 patients treated, nine (90%) reported a subjective reduction in salivation post-treatment and one patient (10%) found no improvement. Visual analogue scale scores showed a reduction of 55% in the mean rate of salivation for all patients and a reduction of 60.8% for the group of responders. No serious adverse events occurred and no procedure related complications were reported. Conclusions - This is the first study to report (1) the injection of BTX-A (BOTOX®) into both parotid and submandibular glands, and (2) the use of ultrasound guidance during the administration of BTX-A into salivary glands. The results suggest that the technique is safe and that BTX-A injections are effective for the treatment of sialorrhoea in patients with neurological disorders.

KW - Botulinum toxin type A

KW - Neurological diseases

KW - Sialorrhoea

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=0035059822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035059822&partnerID=8YFLogxK

U2 - 10.1136/jnnp.70.4.538

DO - 10.1136/jnnp.70.4.538

M3 - Article

VL - 70

SP - 538

EP - 540

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 4

ER -